Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia

Kidney International

Volumn 60, Issue 5, 2001, Pages 1844-1850

  Mezzano, D ^a   Pais, E O ^a   Aranda, E ^a   Panes, O ^a   Downey, P ^a   Ortiz, M ^a   Tagle, R ^a   Gonzalez F ^a   Quiroga, T ^a   Caceres, M S ^a   Leighton, F ^a   Pereira, J ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Cardiovascular disease; Hyperhomocysteinemia; Ischemia; Plasma homocysteine; Thrombosis; Uremia; Vascular lesion

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIPLASMIN; C REACTIVE PROTEIN; CELL MARKER; CREATININE; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; PLASMIN; PROTEIN; PROTEIN DERIVATIVE; PROTHROMBIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COMPLEX FORMATION; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CORRELATION FUNCTION; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; ENDOTHELIUM LESION; FEMALE; FIBRINOLYSIS; FOLIC ACID BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; UREMIA;

EID: 0034783872     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.00998.x     Document Type: Article

References (46)

1. Chronic renal disease: A vasculopathic state
2. Homocysteine in health and disease
3. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
4. The controversy over homocysteine and cardiovascular risk
5. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
6. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients
7. Homocysteine and atherothrombosis
8. Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?
9. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients
10. Advanced oxidation protein products as a novel marker of oxidative stress in uremia
11. Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method
12. Hemostatic disorder of uremia: The platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis
13. Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary disease in patients with chronic renal failure
14. Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients
15. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients
16. Fibrinolytic and inflammatory markers for arterial occlusion: The evolving epidemiology of thrombosis and hemostasis
17. Epidemiological evidence for inflammation in cardiovascular disease
18. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure
19. Endothelial cells in physiology and in the pathophysiology of vascular disorders
20. Hemostatic factors and inflammatory disease
21. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: Relationship with dyslipidemia, inflammation and factor VII genotype
22. Prediction of creatinine clearance from serum creatinine
23. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications
24. Vegetarians and cardiovascular risk factors: Hemostasis, inflammatory markers and plasma homocysteine
25. Tranexamic acid inhibits fibrinolysis, shortens the bleeding time and improves platelet function in patients with chronic renal failure
26. A new thiobarbituric acid (TBA) method for determining free malondialdehyde (MDA) and hydroperoxides selectively as a measure of lipid peroxidation
27. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model
28. The oxidant stress of hyperhomocysteinemia
29. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
30. Induction of monocyte tissue factor expression by homocysteine: A possible mechanism for thrombosis
31. The relationship between homocysteine and superoxide dismutase in homocystinuria: Possible relevance to cardiovascular risk
32. Hyperhomocysteinemia and oxidative stress: Time for a reality check?
33. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia
34. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy
35. Endothelial cell markers in chronic uremia: Relationship with hemostatic defects and severity of renal failure
36. Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: Association with cardiovascular events
37. Homocysteine and thrombotic disease
38. Plasma D dimer: A useful marker of fibrin breakdown in renal failure
39. Tissue plasminogen activator binding to the annexin II tail domain: Direct modulation by homocysteine
40. Homocysteine and other sulfhydril compounds enhance the binding of lipoprotein (a) to fibrin: A potential biochemical link between thrombosis, atherogenesis and sulfhydril compound metabolism
41. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
42. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients
43. Abnormalities of endothelial function in patients with predialysis renal failure
44. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment
45. Increased activation of protein C, but lower plasma levels of free, activated protein C in uraemic patients: Relationship with systemic inflammation and haemostatic activation
46. Homocyst(e)ine and cardiovascular disease: A critical review of the epidemiological evidence